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Abstract
The overall effect of HAART on the liver is the result
of the balance between hepatotoxicity and the conse-
quences of immunoreconstitution on the evolution of
HIv-associated liver diseases, particularly viral hepati-
tis. HAART may lead to the emergence of acute toxic
hepatitis,  steatosis,  steatohepatitis,  liver  fibrosis,  and
noncirrhotic portal hypertension. on the other hand,
HAART use has been associated with slower fibrosis
progression in HIv/HCv-coinfected patients in most
studies dealing with this issue. As well, an improve-
ment of the clinical outcome of liver disease has been
reported in patients taking HAART. For these reasons,
the short- and mid-term effects of HAART on the liv-
er are mostly beneficial.
InTRodUCTIon
It is well-known that HIv-coinfection accelerates the
progression of hepatitis C virus (HCv)-related liver
disease. In fact, while some studies have yielded dis-
cordant results, most reports and two metaanalyses of
nine (Graham CS 2001) and 29 studies (deng L 2009),
respectively, have proven a strong association between
HIv-coinfection  and  an  increased  risk  for  cirrhosis,
end-stage liver disease and death. This effect of HIv
on liver disease progression is clearly related with im-
munosuppression.  Thus,  in  cross-sectional  studies
based on single liver biopsies, patients with lower Cd4
cell counts present more advanced stages of fibrosis
(Benhamou Y 1999, Mac￭as J 2004, Mart￭n Carbonero
L 2004). Likewise, patients with deeper immunosup-
pression  have  poorer  clinical  outcomes  than  those
with higher Cd4 counts (Qurishi n 2003, Merchante
n 2006).
The underlying mechanism of the effect of HIv in-
fection on the progression of HCv-related liver dis-
ease is not completely understood. A study, carried out
in hepatoma cell lines, have shown that HIv and the
surface protein gp120 increase HCv replication and
enhance the expression of TGF b1, a major mediator
in  fibrogenesis.  This  effect  is  blocked  by  antibodies
against co-receptors CCR5 and CXCR4, as well as us-
ing a neutralizing antibody against TGF b1, indicating
that the action of HIv on HCv replication depends
on TGF b1 (Lin W 2008). These findings suggest that
HIv not only increases the replication of HCv, but
also contributes to fibrosis progression. However, in
another study, intrahepatic mRnA levels of inflamma-
tory cytokines were significantly higher in HIv-posi-
tive than in HIv-negative patients harboring hepatitis
C, whereas mRnA levels of profibrogenic cytokines
did  not  differ  between  the  two  groups.  These  facts
support that the accelerated liver disease progression
in  HIv/HCv-coinfected  patients  might  reflect  en-
hanced  intrahepatic  inflammatory  responses  rather
than increased local transcription of directly profibro-
genic cytokines (Kuntzen T 2008). Finally, results re-
ported by our group showed that HIv coinfection in-
creases the expression of Fas receptors in hepatocytes
of HCv carriers, indicating that hepatocyte apoptosis
is enhanced in these patients (Mac￭as J 2005).
Highly active antiretroviral therapy (HAART) leads
to reconstitution of the immune system, which may
improve the control of HCv infection and slow down
the  subsequent  fibrogenesis.  However,  antiretroviral
drugs may also cause several hepatic disorders in the
short  and  long-term,  some  of  them  still  not  well-
known.  Because  of  this,  HAART  might  be  either  a
friend or rather a foe for the liver in HIv/HCv-coin-
fected patients. overall, the effect of HAART on the
liver will be the result of the balance between the ef-
fects of immune reconstitution and those of liver tox-
icity. In the following lines, the toxicity of HAART, as
well as the benefits of this therapy, are analyzed.
LIvER dAMAGE ASSoCIATEd WITH HAART
All antiretroviral drugs may lead to the emergence of
acute  toxic  hepatitis.  However,  most  cases  of  acute
toxic hepatitis are subclinical and spontaneously sub-
side.  These  episodes  of  self-limited  hypertransami-
nasemia do not seem to enhance the progression of
HCv-related  liver  disease.  Thus,  in  a  study  of  116
HIv/HCv-coinfected  patients  with  liver  biopsy  and
previous follow-up, patients with advanced fibrosis did
not  show  peak  elevations  of  ALT  more  commonly
than  subjects  without  advanced  fibrosis  (vergara  S
2007). 
Many issues regarding liver damage associated with
HAART in the long-term are still far from clear. Liver
steatosis is common in HIv/HCv-coinfected patients
under antiretroviral therapy. Some degree of steatosis
is  found  in  up  to  70%  of  liver  biopsies  from
HIv/HCv-coinfected  patients,  with  percentages  of
patients showing steatosis in more than 30% of hepa-
tocytes which range from 2-11% (McGovern B 2006,
neau 2007). The factors associated with the presence
of steatosis in this population, particularly the role of
antiretroviral drugs, are a matter of controversy. It has
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1. Pineda_Umbruchvorlage  16.03.10  13:21  Seite 93been reported that ritonavir treated mice have an in-
crease of the active form of sterol regulatory element-
binding protein (SREBP)-1c in liver cells, which leads
to an increased lipogenesis. In addition, protease in-
hibitors also slow down the intracelular degradation of
APo-B-100, prompting an overproduction of vLdL
particles. Finally, these drugs may inhibit the LdL re-
ceptor-related  protein,  reducing  the  clearance  of
vLdL from circulation (Mooser v 2001). These facts
support  that  protease  inhibitors  might  promote  the
emergence of liver steatosis. However, no study based
on liver biopsy has revealed to date an independent as-
sociation between treatment with protease inhibitors
and the presence of steatosis. Conversely, the use of
dideoxinucleosides,  particularly  d4T,  has  been  found
to  be  an  independent  predictor  of  liver  steatosis  in
several studies (McGovern B 2006, Pascual-Pareja JF
2009,  Sulkowski  2005).  dideoxinucleosides  have  a
high potential for mitochondrial toxicity, which causes
defective  beta-oxidation  of  free  fatty  acids.  Since
steatosis  promotes  the  progression  of  fibrosis,  it  is
conceivable that HIv/HCv-coinfected patients receiv-
ing  drugs  inducing  steatogenesis  will  develop  with
time more severe liver fibrosis. 
HIv-infected patients on HAART show higher lev-
els  of  insulin  resistance  than  those  without  therapy
and healthy controls. This disorder is mainly associat-
ed with treatment with protease inhibitors (Brown TT
2005). Insulin resistance prompts fibrosis progression
in HCv-monoinfected patients. In HIv/HCv-coinfec-
tion, a recent study has shown that patients with high-
er  levels  of  insulin  resistance,  as  measured  by  the
HoMA  method,  harbor  greater  levels  of  liver  stiff-
ness, a reliable marker of fibrosis (Merchante n 2009).
This finding supports that insulin resistance is also a
cofactor  for  fibrosis  progression  in  the  setting  of
HIv/HCv coinfection and also provides a rational to
think that HAART might eventually lead to more se-
vere fibrosis stages. 
In the few last years, an increasing number of cases
of noncirrhotic portal hypertension, observed in HIv-
infected  patients  without  hepatitis  coinfection,  have
been reported (Maida I 2006, Schiano d 2007, Mallet
v 2007). The underlying liver injury has been nodular
regenerative hyperplasia in some of these cases (Mallet
v  2007,  Maida  I  2008)  and  hepatoportal  sclerosis
(Schiano Td 2007) in others. This disorder is believed
to be associated with long-term exposure to didano-
sine (Maida I 2006, Mallet v 2007)  and it seems to
improve  with  the  removal  of  such  a  drug  (Maida  I
2008).  These  data  suggest  that  some  antiretroviral
drugs may cause unexpected liver diseases after years
of exposure. Fortunately, these cases seem to be un-
common. To gain additional knowledge on this topic,
we have screened 258 HIv-infected patients, without
HCv or HBv coinfection, for the presence of liver
stiffness equal to or higher than 7.2 KPa by transient
elastometry. Twenty-nine (11%) subjects showed ab-
normal liver stiffness, according to this threshold. Fif-
teen of them accepted to undergo a liver biopsy and
all of them, but one, had some degree of liver injury
(Fig.  1).  The  most  common  diagnoses  after  biopsy
were alcoholic liver disease and fibrosis of unknown
origin, which reached the stage of cirrhosis in one pa-
tient. Factors independently associated with liver stiff-
ness  equal  to  or  above  7.2  KPa  in  the  multivariate
analysis were: prior exposure to didanosine, exposure
to abacavir, a daily alcohol intake ≥50 g/day, age older
than 40 years and a Cd4 cell count equal to or lower
than 200/mm3. Specifically, the longer the exposure to
didanosine, the higher the liver stiffness. These results
reinforce  the  hypothesis  that  some  antiretroviral
drugs,  like  didanosine,  may  cause  liver  damage  with
long-term exposure.
BEnEFITS oF HAART on THE LIvER In
HIv/HCv CoInFECTIon
Besides  the  above-stated  potential  for  liver  damage,
HAART seems to yield clear benefits to the progres-
sion  of  HCv-related  liver  disease  in  the  short  and
mid-term. Indeed, HAART induces recovery of HCv-
specific T-cell response to HCv core protein, which
parallels with a decline in plasma HCv-RnA load in
HIv/HCv-coinfected  patients  (Rohrbach  J  2009).
This immunological effect correlates with the findings
observed  in  histological  and  clinical  studies.  Thus,
studies analyzing single biopsies have shown that less
severe liver fibrosis is associated with either HAART
(verma  S  2006)  or  the  consequences  of  a  correct
HAART, i. e., higher Cd4 cell count (Benhamou Y
1999, Mac￭as J 2004, Mart￭n-Carbonero L 2004) and
undetectable plasma HIv-RnA load (Br￤u n 2006). 
Longitudinal  studies  have  provided  conflicting  re-
sults about the effect of HAART on the progression
of liver fibrosis. Thus, a study based on paired biopsies
taken from 174 patients belonging to the cohort of the
Johns Hopkins University showed no association be-
tween  HAART  and  changes  in  the  fibrosis  stage
(Sulkowski 2007). Moreover, a recent study, in which
APRI was sequentially measured, showed that HAART
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Fig. 1. diagnosis in HIv-infected patients without HCv or
HBv coinfection, showing liver stiffness ≥7.2 KPa, and who
underwent liver biopsy (n = 15).
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time in HIv/HCv co-infected patients. According to
the opinion of the authors, this finding would suggest
that patients might be experiencing cumulative hepato-
toxicity from antiretrovirals (Moodie EEM 2009). To
further clarify this topic, we have studied paired biop-
sies from 135 HIv/HCv-coinfected patients studied in
nine  hospitals  in  Spain.  The  median  time  between
biopsies was 3.3 years. overall, 44% of patients pro-
gressed  at  least  one  fibrosis  stage  of  the  Scheuer’s
scoring system, including 56% of those who showed
F0 or F1 at the initial biopsy. The factors independent-
ly associated with lack of fibrosis progression were low
necroinflamatory  activity  at  the  first  biopsy,  longer
time from the baseline to the final sample, response to
HCv therapy and undetectable plasma HIv-RnA be-
tween biopsies (Table 1). The latter results show that a
correct HAART slow down HCv-related fibrosis pro-
gression in HIv-coinfected patients.
Researchers  which  have  assessed  the  clinical  out-
come  in  patients  with  HIv/HCv  coinfection  have
uniformly found results consistent with the histologi-
cal  benefit  observed  in  the  above-mentioned  study.
Thus, in the Bonn and in the San Francisco cohorts,
HAART was associated with a lower liver related mor-
tality (Qurishi n 2003, Bonacini M 2004). This benefi-
cial effect has also been reported even in the most ad-
vanced  stages  of  liver  disease  (Merchante  n  2006).
Accordingly, a greater increase of Cd4 cell count after
starting HAART has been found to be associated with
a  reduced  incidence  of  liver  decompensation  and  a
longer survival (Pineda JA 2007). 
Studies appraising the impact of specific antiretro-
viral drugs on liver fibrosis progression have yielded
conflicting results. In fact, whereas some studies have
reported that the rate of fibrosis progression in pa-
tients taking protease inhibitors is slower than in those
receiving  nevirapine  (Mac￭as  J  2004),  other  studies
have found the opposite results (Berenguer J 2008) or
no association at all between specific drugs and fibro-
sis  progression  (Martin-Carbonero  2004,  verma  S
2006). However, all these are retrospective studies and
inherent biases likely explain the controversial results.
This topic will remain unclear, unless a specific ran-
domized clinical trial to assess it is undertaken.
The beneficial effect of HAART on the progres-
sion of HCv infection has made the outcome of liver
disease in HIv/HCv-coinfected patients more similar
to that of HCv-monoinfected subjects than it used to
be before the HAART era. However, HIv still nega-
tively affects the progression of liver disease in HCv
carriers.  Thus,  a  recent  metaanalysis,  where  studies
carried out in patients with and without HAART were
analyzed separately, found that the course of HCv in-
fection continues to be worse in HCv/HIv-coinfect-
ed patients taking HAART. However the risk ratio for
cirrhosis between coinfected and HCv-monoinfected
patients  has  declined  from  2.49  in  patients  without
HAART to 1.72 in those receiving HAART (Thein H
2008).
ConCLUSIonS
There are data showing that the use of HAART is as-
sociated with several sorts of liver injuries. This fact is
certainly a threat of an increased rate of serious liver
disorders in the setting of HIv/HCv-coinfected pa-
tients. However, the effects of HAART on liver fibro-
sis progression in these patients are clearly beneficial,
at  least  in  the  short  and  mid-term.  Ithe  use  of
HAART is likely one of the reasons why the mortality
due  to  liver  disease  has  stopped  increasing  among
HIv-infected patients seen in places where HCv-coin-
fection is a major problem (del valle J 2008, n￺￱ez-
Fern￡ndez  C  2009).  Because  of  this,  the  effects  of
HAART on the progression of HCv-related liver dis-
ease in coinfected patients largely outweigh the poten-
tial risks for long-term toxicity. Accordingly, an earlier
starting of ART in patients with HIv/HCv-coinfec-
tion is sufficiently justified.
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